ANAVEX LIFE SCIENCES CORP. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
ANAVEX LIFE SCIENCES CORP. (AVXL) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 3.68% for the 9-month period ending 2026-06-30, per its 10-Q filed 2026-08-28.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2026-08-28
- ANAVEX LIFE SCIENCES CORP. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2025-12-31 was 3.88%.
- ANAVEX LIFE SCIENCES CORP. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2024-12-31 was 0.00%, a 100.00% decline year-over-year.
- ANAVEX LIFE SCIENCES CORP. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2023-12-31 was 4.47%, a 9.83% increase year-over-year.
- ANAVEX LIFE SCIENCES CORP. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2022-12-31 was 4.07%, a 197.08% increase year-over-year.
- ANAVEX LIFE SCIENCES CORP. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2025 was 3.98%, a 7.01% decline from fiscal 2024.
- ANAVEX LIFE SCIENCES CORP. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2024 was 4.28%, a 15.68% increase from fiscal 2023.
- ANAVEX LIFE SCIENCES CORP. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2023 was 3.70%, a 18.97% increase from fiscal 2022.
- ANAVEX LIFE SCIENCES CORP. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2022 was 3.11%, a 326.03% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | 3.68% 10-Q · filed 2026-08-28 | ||||
| 2026-03-31 | 3.68% 10-Q · filed 2026-08-28 | ||||
| 2025-12-31 | 3.88% 10-Q · filed 2026-02-09 | ||||
| 2025-09-30 | 3.98% 10-K/A · filed 2026-08-28 | ||||
| 2025-06-30 | 3.98% 10-Q · filed 2026-08-28 | ||||
| 2025-03-31 | 3.98% 10-Q · filed 2026-08-28 | ||||
| 2024-12-31 | 0.00% 10-Q · filed 2026-02-09 | ||||
| 2024-09-30 | 4.28% 10-K/A · filed 2026-08-28 | ||||
| 2024-06-30 | 4.29% 10-Q · filed 2025-08-12 | ||||
| 2024-03-31 | 4.28% 10-Q · filed 2025-05-13 | ||||
| 2023-12-31 | 4.47% 10-Q · filed 2025-02-12 | ||||
| 2023-09-30 | 3.70% 10-K/A · filed 2026-08-28 | ||||
| 2023-06-30 | 3.69% 10-Q · filed 2024-08-06 | ||||
| 2023-03-31 | 3.69% 10-Q · filed 2024-05-09 | ||||
| 2022-12-31 | 4.07% 10-Q · filed 2024-02-07 | ||||
| 2022-09-30 | 3.11% 10-K · filed 2023-11-27 | ||||
| 2022-06-30 | 3.10% 10-Q · filed 2023-08-08 | ||||
| 2022-03-31 | 1.40% 10-Q · filed 2023-05-09 | ||||
| 2021-12-31 | 1.37% 10-Q · filed 2023-02-07 | ||||
| 2021-09-30 | 0.73% 10-K · filed 2023-11-27 | ||||
| 2021-06-30 | 0.71% 10-Q · filed 2022-08-09 | ||||
| 2021-03-31 | 0.64% 10-Q · filed 2022-05-10 | ||||
| 2020-12-31 | 0.62% 10-Q · filed 2022-02-09 | ||||
| 2020-09-30 | 1.57% 10-K · filed 2022-11-28 | ||||
| 2020-06-30 | 1.57% 10-Q · filed 2021-08-12 | ||||
| 2020-03-31 | 1.68% 10-Q · filed 2021-05-13 | ||||
| 2019-12-31 | 1.88% 10-Q · filed 2021-02-16 | ||||
| 2019-09-30 | 2.50% 10-K · filed 2020-12-28 | ||||
| 2019-06-30 | 2.91% 10-Q · filed 2020-08-06 | 2.51% 10-Q · filed 2019-08-07 | |||
| 2019-03-31 | 2.91% 10-Q · filed 2020-05-07 | ||||
| 2018-12-31 | 2.96% 10-Q · filed 2020-02-06 | ||||
| 2018-09-30 | 2.73% 10-K · filed 2019-12-16 | ||||
| 2018-06-30 | 2.73% 10-Q · filed 2019-08-07 | ||||
| 2018-03-31 | 2.43% 10-Q · filed 2019-05-09 | ||||
| 2017-12-31 | 2.26% 10-Q · filed 2019-02-07 | ||||
| 2017-09-30 | 2.11% 10-K · filed 2019-01-25 | ||||
| 2017-06-30 | 1.98% 10-Q · filed 2018-08-09 | ||||
| 2017-03-31 | 1.76% 10-Q · filed 2018-05-10 | ||||
| 2016-12-31 | 1.52% 10-Q · filed 2018-02-07 | ||||
| 2016-09-30 | 1.28% 10-K · filed 2019-01-25 | ||||
| 2016-06-30 | 1.67% 10-Q · filed 2017-08-07 | ||||
| 2016-03-31 | 1.68% 10-Q · filed 2016-05-11 | ||||
| 2015-12-31 | 1.66% 10-Q · filed 2017-02-07 | ||||
| 2015-09-30 | 1.63% 10-K · filed 2017-12-11 | ||||
| 2015-06-30 | 1.53% 10-Q · filed 2016-08-11 | ||||
| 2014-09-30 | 2.27% 10-K · filed 2016-12-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |